+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Fibroblast Growth Factors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2031 - (By Product Coverage, Application Coverage, End User Coverage, Geographic Coverage and By Company)

  • PDF Icon

    Report

  • 185 Pages
  • April 2024
  • Region: Global
  • Fairfield Market Research
  • ID: 5908966
Description Jump to:
Global fibroblast growth factors (FGF) market is projected to witness substantial growth, with market size expected to surge to US$500 million by 2031 from approximately US$280 million in 2024. This forecast reflects an impressive compound annual growth rate (CAGR) of 8.64% during the period spanning 2024 to 2031.

Quick Report Digest

  • Significant Revenue Surge: The market anticipates more than a 1.7x expansion in revenue between 2024 and 2031.
  • Diverse Applications: FGFs are applied in wound healing, tissue regeneration, oncology, dermatology, with burgeoning therapeutic potential in cardiovascular diseases and neurological disorders.
  • Growth Drivers: Expansion is fueled by increased healthcare expenditure, technological advancements in biotechnology, and widening applications across therapeutic areas.
  • Challenges: Regulatory hurdles, safety concerns regarding adverse effects, and limited commercialization infrastructure pose challenges.
  • Industry Trends: Notable trends include personalized medicine in oncology, collaborative research initiatives, and expanded therapeutic applications.
  • Opportunities: Exploration of novel therapeutic applications and expansion into emerging markets like the Asia Pacific present significant growth opportunities.
  • Regional Insights: North America leads, followed by Europe and the Asia Pacific, while the Rest of the World shows potential with evolving healthcare infrastructure.
  • Key Players: Major industry players such as Amgen, Pfizer, and Johnson & Johnson dominate the market with continuous R&D efforts, strategic partnerships, and innovative product development.
  • Notable Developments: Notable developments include Amgen's RegenFibra™ for diabetic foot ulcers, Pfizer's RejuvaGlow™ dermal filler, and Johnson & Johnson's orthopaedic implants distribution agreement.

Key Growth Determinants

  • Expanding Applications: FGFs exhibit significant growth due to expanding applications across various therapeutic areas, including wound healing, tissue regeneration, oncology, and beyond.
  • Technological Advancements: Continuous advancements in biotechnology and genetic engineering are enhancing the production and delivery of FGF products, driving market growth.
  • Increasing Healthcare Expenditure: Rising healthcare expenditure Globally, coupled with growing awareness about the potential benefits of FGF therapies, contributes to market expansion.

Major Growth Barriers

  • Regulatory Hurdles: Stringent regulatory requirements for FGF-based therapies pose significant restraints on market growth.
  • Safety Concerns: Despite therapeutic potential, safety concerns regarding adverse effects limit clinical utility.
  • Limited Commercialization Infrastructure: Lack of established infrastructure for FGF product commercialization hinders market growth.

Key Trends and Opportunities to Look at

  • The Personalized Medicine Boom: Shift towards personalized medicine enables tailored treatment strategies, particularly in oncology.
  • Collaborative Research Initiatives: Increasing emphasis on collaborative research initiatives accelerates innovation in FGF therapies.
  • Expanded Therapeutic Applications: Opportunities exist in exploring novel therapeutic applications beyond traditional indications.
  • Global Market Penetration: Emerging markets offer significant growth potential for FGF market players.

Regional Frontrunners

  • North America: Dominates with established regulatory frameworks and high healthcare expenditure.
  • Europe: Presents a compelling market with significant government funding fostering innovation.
  • Asia Pacific: Holds immense promise due to a rapidly ageing population and rising disposable income.

The Competitive Landscape Analysis

The fibroblast growth factors market is fiercely competitive, with leaders such as Amgen Inc., Pfizer Inc., and Johnson & Johnson dominating. Key growth strategies include product development, strategic partnerships, and market expansion initiatives.

Leaders in Global Fibroblast Growth Factors Space

  • Thermo Fisher Scientific
  • Sigma-Aldrich (now part of Merck KGaA)
  • PeproTech
  • R&D Systems (a Bio-Techne brand)
  • Abcam
  • Cell Signaling Technology
  • Novus Biologicals

Global fibroblast growth factors market is Segmented as Below:

By Product:

  • FGF1
  • FGF2
  • FGF3
  • FGF4
  • FGF7
  • FGF10
  • FGF11
  • FGF12
  • FGF13
  • FGF14
  • FGF15
  • FGF18
  • FGF19
  • FGF20
  • FGF23

By Application:

  • Oncology
  • Hematology
  • Wound Healing
  • Dermatology
  • Cardiovascular Disease & Diabetes
  • Cell Culture

By End User:

  • Pharmaceutical and Biotechnology Companies
  • Research Centers & Academic Institutes
  • CMO and CDMO

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (Middle East and Africa)


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Fibroblast Growth Factors Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Fibroblast Growth Factors Market Outlook, 2019 - 2031
3.1. Global Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
3.1.1. Key Highlights
3.1.1.1. FGF1
3.1.1.2. FGF2
3.1.1.3. FGF3
3.1.1.4. FGF4
3.1.1.5. FGF7
3.1.1.6. FGF10
3.1.1.7. FGF11
3.1.1.8. FGF12
3.1.1.9. FGF13
3.1.1.10. FGF14
3.1.1.11. FGF15
3.1.1.12. FGF18
3.1.1.13. FGF19
3.1.1.14. FGF20
3.1.1.15. FGF23
3.1.1.16. Others
3.2. Global Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
3.2.1. Key Highlights
3.2.1.1. Oncology
3.2.1.2. Hematology
3.2.1.3. Wound Healing
3.2.1.4. Dermatology
3.2.1.5. Cardiovascular Disease & Diabetes
3.2.1.6. Cell Culture
3.2.1.7. Others
3.3. Global Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
3.3.1. Key Highlights
3.3.1.1. Pharmaceutical & Biotechnology Companies
3.3.1.2. Research Centers & Academic Institutes
3.3.1.3. CMOs & CDMOs
3.4. Global Fibroblast Growth Factors Market Outlook, by Region, Value (US$ Bn), 2019 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Fibroblast Growth Factors Market Outlook, 2019 - 2031
4.1. North America Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
4.1.1. Key Highlights
4.1.1.1. FGF1
4.1.1.2. FGF2
4.1.1.3. FGF3
4.1.1.4. FGF4
4.1.1.5. FGF7
4.1.1.6. FGF10
4.1.1.7. FGF11
4.1.1.8. FGF12
4.1.1.9. FGF13
4.1.1.10. FGF14
4.1.1.11. FGF15
4.1.1.12. FGF18
4.1.1.13. FGF19
4.1.1.14. FGF20
4.1.1.15. FGF23
4.1.1.16. Others
4.2. North America Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
4.2.1. Key Highlights
4.2.1.1. Oncology
4.2.1.2. Hematology
4.2.1.3. Wound Healing
4.2.1.4. Dermatology
4.2.1.5. Cardiovascular Disease & Diabetes
4.2.1.6. Cell Culture
4.2.1.7. Others
4.3. North America Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
4.3.1. Key Highlights
4.3.1.1. Pharmaceutical & Biotechnology Companies
4.3.1.2. Research Centers & Academic Institutes
4.3.1.3. CMOs & CDMOs
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
4.4.1.2. U.S. Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
4.4.1.3. U.S. Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
4.4.1.4. Canada Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
4.4.1.5. Canada Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
4.4.1.6. Canada Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Fibroblast Growth Factors Market Outlook, 2019 - 2031
5.1. Europe Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
5.1.1. Key Highlights
5.1.1.1. FGF1
5.1.1.2. FGF2
5.1.1.3. FGF3
5.1.1.4. FGF4
5.1.1.5. FGF7
5.1.1.6. FGF10
5.1.1.7. FGF11
5.1.1.8. FGF12
5.1.1.9. FGF13
5.1.1.10. FGF14
5.1.1.11. FGF15
5.1.1.12. FGF18
5.1.1.13. FGF19
5.1.1.14. FGF20
5.1.1.15. FGF23
5.1.1.16. Others
5.2. Europe Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
5.2.1. Key Highlights
5.2.1.1. Oncology
5.2.1.2. Hematology
5.2.1.3. Wound Healing
5.2.1.4. Dermatology
5.2.1.5. Cardiovascular Disease & Diabetes
5.2.1.6. Cell Culture
5.2.1.7. Others
5.3. Europe Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
5.3.1. Key Highlights
5.3.1.1. Pharmaceutical & Biotechnology Companies
5.3.1.2. Research Centers & Academic Institutes
5.3.1.3. CMOs & CDMOs
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
5.4.1.2. Germany Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
5.4.1.3. Germany Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
5.4.1.4. U.K. Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
5.4.1.5. U.K. Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
5.4.1.6. U.K. Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
5.4.1.7. France Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
5.4.1.8. France Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
5.4.1.9. France Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
5.4.1.10. Italy Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
5.4.1.11. Italy Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
5.4.1.12. Italy Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
5.4.1.13. Turkey Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
5.4.1.14. Turkey Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
5.4.1.15. Turkey Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
5.4.1.16. Russia Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
5.4.1.17. Russia Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
5.4.1.18. Russia Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
5.4.1.19. Rest of Europe Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
5.4.1.20. Rest of Europe Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
5.4.1.21. Rest of Europe Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Fibroblast Growth Factors Market Outlook, 2019 - 2031
6.1. Asia Pacific Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
6.1.1. Key Highlights
6.1.1.1. FGF1
6.1.1.2. FGF2
6.1.1.3. FGF3
6.1.1.4. FGF4
6.1.1.5. FGF7
6.1.1.6. FGF10
6.1.1.7. FGF11
6.1.1.8. FGF12
6.1.1.9. FGF13
6.1.1.10. FGF14
6.1.1.11. FGF15
6.1.1.12. FGF18
6.1.1.13. FGF19
6.1.1.14. FGF20
6.1.1.15. FGF23
6.1.1.16. Others
6.2. Asia Pacific Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
6.2.1. Key Highlights
6.2.1.1. Oncology
6.2.1.2. Hematology
6.2.1.3. Wound Healing
6.2.1.4. Dermatology
6.2.1.5. Cardiovascular Disease & Diabetes
6.2.1.6. Cell Culture
6.2.1.7. Others
6.3. Asia Pacific Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
6.3.1. Key Highlights
6.3.1.1. Pharmaceutical & Biotechnology Companies
6.3.1.2. Research Centers & Academic Institutes
6.3.1.3. CMOs & CDMOs
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
6.4.1. Key Highlights
6.4.1.1. China Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
6.4.1.2. China Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
6.4.1.3. China Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
6.4.1.4. Japan Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
6.4.1.5. Japan Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
6.4.1.6. Japan Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
6.4.1.7. South Korea Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
6.4.1.8. South Korea Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
6.4.1.9. South Korea Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
6.4.1.10. India Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
6.4.1.11. India Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
6.4.1.12. India Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
6.4.1.13. Southeast Asia Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
6.4.1.14. Southeast Asia Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
6.4.1.15. Southeast Asia Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
6.4.1.16. Rest of Asia Pacific Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
6.4.1.17. Rest of Asia Pacific Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
6.4.1.18. Rest of Asia Pacific Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Fibroblast Growth Factors Market Outlook, 2019 - 2031
7.1. Latin America Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
7.1.1. Key Highlights
7.1.1.1. FGF1
7.1.1.2. FGF2
7.1.1.3. FGF3
7.1.1.4. FGF4
7.1.1.5. FGF7
7.1.1.6. FGF10
7.1.1.7. FGF11
7.1.1.8. FGF12
7.1.1.9. FGF13
7.1.1.10. FGF14
7.1.1.11. FGF15
7.1.1.12. FGF18
7.1.1.13. FGF19
7.1.1.14. FGF20
7.1.1.15. FGF23
7.1.1.16. Others
7.2. Latin America Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
7.2.1. Key Highlights
7.2.1.1. Oncology
7.2.1.2. Hematology
7.2.1.3. Wound Healing
7.2.1.4. Dermatology
7.2.1.5. Cardiovascular Disease & Diabetes
7.2.1.6. Cell Culture
7.2.1.7. Others
7.3. Latin America Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
7.3.1. Key Highlights
7.3.1.1. Pharmaceutical & Biotechnology Companies
7.3.1.2. Research Centers & Academic Institutes
7.3.1.3. CMOs & CDMOs
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
7.4.1.2. Brazil Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
7.4.1.3. Brazil Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
7.4.1.4. Mexico Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
7.4.1.5. Mexico Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
7.4.1.6. Mexico Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
7.4.1.7. Argentina Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
7.4.1.8. Argentina Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
7.4.1.9. Argentina Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
7.4.1.10. Rest of Latin America Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
7.4.1.11. Rest of Latin America Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
7.4.1.12. Rest of Latin America Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Fibroblast Growth Factors Market Outlook, 2019 - 2031
8.1. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
8.1.1. Key Highlights
8.1.1.1. FGF1
8.1.1.2. FGF2
8.1.1.3. FGF3
8.1.1.4. FGF4
8.1.1.5. FGF7
8.1.1.6. FGF10
8.1.1.7. FGF11
8.1.1.8. FGF12
8.1.1.9. FGF13
8.1.1.10. FGF14
8.1.1.11. FGF15
8.1.1.12. FGF18
8.1.1.13. FGF19
8.1.1.14. FGF20
8.1.1.15. FGF23
8.1.1.16. Others
8.2. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
8.2.1. Key Highlights
8.2.1.1. Oncology
8.2.1.2. Hematology
8.2.1.3. Wound Healing
8.2.1.4. Dermatology
8.2.1.5. Cardiovascular Disease & Diabetes
8.2.1.6. Cell Culture
8.2.1.7. Others
8.3. Middle East & Africa Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
8.3.1. Key Highlights
8.3.1.1. Pharmaceutical & Biotechnology Companies
8.3.1.2. Research Centers & Academic Institutes
8.3.1.3. CMOs & CDMOs
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
8.4.1.2. GCC Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
8.4.1.3. GCC Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
8.4.1.4. South Africa Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
8.4.1.5. South Africa Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
8.4.1.6. South Africa Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
8.4.1.7. Egypt Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
8.4.1.8. Egypt Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
8.4.1.9. Egypt Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
8.4.1.10. Nigeria Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
8.4.1.11. Nigeria Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
8.4.1.12. Nigeria Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
8.4.1.13. Rest of Middle East & Africa Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
8.4.1.14. Rest of Middle East & Africa Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
8.4.1.15. Rest of Middle East & Africa Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By End User vs by Application Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Thermo Fisher Scientific
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Sigma-Aldrich (now part of Merck KGaA)
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. PeproTech
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. R&D Systems (a Bio-Techne brand)
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Abcam
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Cell Signaling Technology
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Novus Biologicals
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Thermo Fisher Scientific
  • Sigma-Aldrich (now part of Merck KGaA)
  • PeproTech
  • R&D Systems (a Bio-Techne brand)
  • Abcam
  • Cell Signaling Technology
  • Novus Biologicals

Methodology

Loading
LOADING...

Related Topics

Related Reports

Fibroblast Growth Factor 1 (FGF-1) Inhibitor - Pipeline Insight, 2024 - Product Image

Fibroblast Growth Factor 1 (FGF-1) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Type-2 fibroblast growth factor receptor antagonists - Pipeline Insight, 2024 - Product Image

Type-2 fibroblast growth factor receptor antagonists - Pipeline Insight, 2024

  • Drug Pipelines
  • 70 Pages
  • Global
From
Fibroblast Growth Factor Receptor Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology - Product Image

Fibroblast Growth Factor Receptor Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology

  • Report
  • 97 Pages
  • Global
From
Fibroblast Growth Factor 23 - Product Image

Fibroblast Growth Factor 23

  • Book
Fibroblast Growth Factors. Edition No. 2 - Product Image

Fibroblast Growth Factors. Edition No. 2

  • Book
Copyright © 2002-2024 Research and Markets. All Rights Reserved.